Is At-Home Ketamine Therapy as Effective as Clinic Treatment?

This is the question I hear most often from patients researching ketamine therapy: is taking a tablet at home really as effective as getting an IV infusion at a clinic? It is a fair question, and you deserve an honest, evidence-based answer rather than marketing spin from either side of the debate.

As a physician who prescribes at-home ketamine therapy, I have a clear perspective on this, but I also have an obligation to present the full picture. The comparison between at-home sublingual ketamine and in-clinic IV ketamine involves trade-offs in bioavailability, clinical outcomes, safety, convenience, cost, and treatment adherence. Let me walk through each.

Bioavailability: The Numbers in Context

Bioavailability refers to the percentage of a drug that reaches your bloodstream and becomes available to produce its effects. This is where the most common argument against at-home therapy originates.

IV ketamine has 100 percent bioavailability by definition --- the drug goes directly into your bloodstream.

Sublingual ketamine (dissolved under the tongue) has a bioavailability of approximately 25 to 35 percent, depending on how long the tablet is held in place and individual variation in absorption.

At first glance, this seems like a decisive advantage for IV administration. But bioavailability alone does not determine clinical effectiveness, and focusing on this single metric misses several important considerations.

Dosing compensates for bioavailability differences. Sublingual ketamine is prescribed at doses that account for lower bioavailability. A patient receiving sublingual ketamine is given a dose calibrated to deliver a therapeutically effective amount of the drug to the brain. The prescribing physician is not handing you a fraction of a useful dose --- the bioavailability is factored into the prescription.

Blood level kinetics differ. IV ketamine produces a rapid, high peak blood level followed by a relatively quick decline. Sublingual ketamine produces a lower but more sustained blood level over a longer period. Some researchers have suggested that this more gradual absorption pattern may actually support neuroplasticity by providing a longer duration of NMDA receptor modulation.

What matters is what happens at the receptor. The therapeutic effects of ketamine depend on what happens at NMDA receptors and in downstream neuroplastic cascades, not on peak blood levels per se. Both routes of administration achieve sufficient receptor occupancy to trigger these therapeutic mechanisms.

For a deeper understanding of ketamine's mechanism of action, visit our page on how ketamine works.

Clinical Outcomes: What the Evidence Shows

The most important question is not how much ketamine reaches your blood but whether the treatment improves your depression, anxiety, or PTSD. Here is what the research tells us.

Real-world outcome data from large patient populations treated with at-home sublingual ketamine shows response rates that are comparable to those reported in IV ketamine studies. Response rates (typically defined as a 50 percent or greater reduction in depression severity scores) in published sublingual ketamine studies range from 50 to 70 percent, which overlaps substantially with the response rates reported in IV ketamine trials.

Head-to-head comparisons are limited but growing. The studies that have directly compared sublingual and IV ketamine have generally found comparable antidepressant outcomes, though the onset of response may be slightly faster with IV administration due to the immediate peak blood levels.

Remission rates --- meaning patients who achieve full resolution of depressive symptoms rather than just improvement --- also appear comparable between the two routes in available data.

Duration of benefit. Both sublingual and IV ketamine require ongoing treatment to maintain their benefits. Neither route offers a permanent cure from a single session or course. The at-home model may have an advantage here because it supports more consistent, ongoing treatment without the logistical barriers of repeated clinic visits.

It is important to acknowledge that most ketamine research has been conducted using IV administration, simply because that was the standard route when studies began. The evidence base for sublingual ketamine is growing rapidly but is less extensive than for IV. This does not mean sublingual is less effective --- it means it was studied later.

Safety Comparison

Safety is where nuance matters most.

Medical monitoring during sessions. In-clinic IV ketamine is administered with a nurse or physician present who monitors vital signs throughout the infusion. At-home sublingual therapy does not include in-person medical supervision during each session. This is a genuine difference.

However, the safety profile of sublingual ketamine at the doses prescribed for at-home therapy is well established. The lower, more gradual blood levels associated with sublingual administration produce milder acute effects (dissociation, blood pressure changes, sedation) compared to IV infusions. Patients are screened for cardiovascular and psychiatric risk factors before beginning treatment, and ongoing monitoring through regular telehealth check-ins catches issues that require intervention.

Our comprehensive safety protocols detail how we mitigate risks in the at-home setting.

Blood pressure. Ketamine can cause transient blood pressure elevation. At-home patients are asked to monitor their blood pressure before and after sessions. The blood pressure increases seen with sublingual dosing are typically more modest than those seen with IV infusions.

Dissociation. Both routes produce dissociative effects, but the intensity is generally lower with sublingual administration. Most at-home patients describe the experience as a mild to moderate altered state that resolves within one to two hours.

FDA safety context. In 2022, the FDA issued a safety communication regarding compounded ketamine products, noting the lack of FDA approval for compounded ketamine for psychiatric conditions. This communication was specifically about the regulatory status of compounded medications, not a finding that at-home ketamine therapy is unsafe. Compounded medications are legal, regulated by state pharmacy boards, and widely used across many areas of medicine. The FDA-approved form, Spravato (esketamine nasal spray), must be administered in a certified healthcare setting under direct supervision, but this reflects regulatory requirements rather than a finding that other routes of ketamine administration are inherently dangerous.

The Convenience Factor

Convenience may sound like a secondary consideration, but in practice, it profoundly affects treatment outcomes through its impact on adherence.

Treatment adherence. The most effective treatment in the world does not work if patients cannot maintain it. In-clinic IV ketamine requires traveling to a clinic, sitting for a one to two-hour infusion, and having someone drive you home afterward --- typically two to three times per week during the initial phase. For patients with demanding jobs, family responsibilities, physical disabilities, chronic pain, or transportation limitations, this schedule can be unsustainable.

At-home sublingual therapy eliminates these barriers. You take your medication in your own home, on a schedule that fits your life. There is no commute, no waiting room, no need for a driver. This practical accessibility translates directly into better adherence and, consequently, better outcomes for many patients.

Consistency of treatment. Depression is a chronic condition that often requires long-term management. The at-home model supports sustained treatment over months and years in a way that repeated clinic visits may not. Many patients who begin IV ketamine at a clinic eventually transition to at-home sublingual therapy for maintenance precisely because of the convenience factor.

Comfort and setting. Some patients find the clinical environment anxiety-provoking, which can work against the therapeutic goals of treatment. Being in your own home, in a familiar and comfortable environment, can reduce session-related anxiety and allow for a more positive treatment experience. Our what to expect page walks through how to set up your home for optimal sessions.

The Physician Oversight Model

A common concern about at-home therapy is whether patients receive adequate medical oversight. At Tovani Health, the physician oversight model is designed to be rigorous despite the at-home setting.

Initial evaluation. Every patient undergoes a comprehensive medical and psychiatric evaluation before treatment begins. We review your complete medical history, current medications, mental health diagnoses, cardiovascular health, and any contraindications to ketamine therapy.

Ongoing monitoring. Regular telehealth check-ins allow us to assess your response, adjust dosing, manage side effects, and address any concerns. These are not cursory check-boxes --- they are genuine clinical encounters where treatment decisions are made based on your evolving needs.

Clear safety protocols. Patients receive explicit guidance on when to hold a dose, when to contact our team, and when to seek emergency care. You are never left to figure things out on your own.

Responsive communication. Our medical team is accessible between scheduled appointments for questions and concerns. If something does not feel right, you can reach us without waiting for your next scheduled visit.

Full cost and coverage information is available so you can evaluate the financial aspect alongside clinical considerations.

Making Your Decision

Both in-clinic IV ketamine and at-home sublingual ketamine are legitimate treatment options with evidence supporting their effectiveness. The right choice depends on your individual circumstances.

In-clinic IV ketamine may be preferable if you have significant cardiovascular risk factors that warrant in-person monitoring, you prefer having medical staff physically present during sessions, you respond specifically to IV administration after trying sublingual, or you have access to a high-quality clinic at a price you can sustain long-term.

At-home sublingual ketamine may be preferable if you need scheduling flexibility, you live far from a ketamine clinic, you find clinical settings anxiety-provoking, cost is a significant factor, you need a treatment model that supports long-term maintenance, or privacy is particularly important to you.

Neither option is inherently superior. What matters is that you receive evidence-based treatment with proper physician oversight, consistent adherence, and ongoing monitoring of your response.

If you are ready to explore whether at-home ketamine therapy is the right fit for your situation, I encourage you to check your eligibility with Tovani Health. We will give you an honest assessment of whether our treatment model is appropriate for your specific needs, and if it is not, we will help you find the right path forward.